Abstract A weighted enzymatic chip array (WEnCA) can detect the gene expression of circulating tumor cells (CTCs) in the peripheral blood of patients with colorectal cancer (CRC). In this study, we used a reagent kit, the GeneCling CRC Enzymatic Gene Chip Detection Kit, which was specifically developed for the WEnCA operation platform to analyze the expression of 31 CRCrelated genes of CTCs in the peripheral blood of 30 CRC patients. We moreover evaluated the expression of the genes by simultaneously using real-time quantitative polymerase chain reaction (RT-QPCR). The results showed the overexpression rate of nine genesdDVL1, ELAVL4, CHRNB1, UBE2C, PSAT1, CEA, PTTG1, KRT19, and hTERTdwas greater than 90% in the CRC patients. This is concordant with the results of the original WEnCA operation procedure. Linear regression analysis demonstrated a high correlation (r Z 0.901; p < 0.0001) between the experimental data of the detection kit and RT-QPCR. The GeneCling CRC Enzymatic Gene Chip Detection Kit is easy, fast, and convenient to operate for detecting gene expression of CTCs from peripheral blood. However, the correlation between the differential expression and the clinicopathological features of the 31 CRC-related genes needs further investigation to verify the clinical value.
Introduction
Colorectal cancer (CRC) is the most common tumor in the world. 1 In Taiwan, CRC is one of the most frequent malignancies and the third major cause of cancer death. 2 The diagnosis and surgical treatments for CRC have improved in recent years; however, the patient survival rate remains low. This is primarily because of the consistently poor prognosis of patients who have an advanced stage of CRC. 3, 4 Approximately 40e50% of CRC patients who undergo a supposedly curative resection subsequently develop metastatic disease and die of their disease within 5 years. 5, 6 Therefore, early diagnosis is imperative for obtaining a better therapeutic outcome and prognosis.
Recent studies have shown that detecting the molecular markers of circulating tumor cells (CTCs) in the peripheral blood of CRC patients may be useful for cancer diagnosis, prognosis assessment, or postoperative follow-up assessments. 7 Common techniques used for detecting the molecular markers of CTCs are polymerase chain reaction (PCR), reverse transcriptaseePCR (RT-PCR), or real-time quantitative PCR (RT-QPCR) assays. Analyzing a single biomarker only provides limited sensitivity and specificity. The combination of multiple biomarkers may be able to improve diagnosis in patients. 8, 9 The weighted enzymatic chip array (WEnCA) platform that we developed in our previous study can detect CTCs in the peripheral blood of CRC patients. We also demonstrated a high correlation between the RT-QPCR and the WEnCA method in detecting CTCs in CRC patients. 10 In our previously study, we found that the WEnCA platform has a high sensitivity and specificity for detecting activated KRAS expression in CRC patients. 11 The WEnCA platform requires many commercial kits so that whole experiments can be performed, which is inconvenient and requires much time to accomplish the test conditions of the experiments. If the reagent kit is used exclusively for the platform, the WEnCA could be easy to operate and could increase stability. In this study, we used the GeneCling Enzymatic Gene Chip Detection Kit (MedicoGene Biotechnology Corp., Los Angeles, LA, USA)da reagent kit specifically developed for the WEnCA platformdto analyze the gene expression of CTCs in the peripheral blood of CRC patients. We also analyzed gene expression by using RT-QPCR. We then determined the degree of consistency between the two methods.
Materials and methods

Patients and sample collection
Whole blood samples were collected from 30 colorectal cancer patients who had undergone surgical resection. 
GenCling Enzymatic Gene Chip Detection Kit
Based on our previous study, 12 we selected 31 candidate genes that are most closely related to CRC to develop and construct a gene chip. Oligonucleotide sequences were design by VectorNTI software (Life Technologies Corp., Grand Island, NY, USA). The newly synthesized oligonucleotide fragments were dissolved in deionized distilled water and then blotted in trip licate on Nytran SuPerCharge nylon membrane (Schleicher and Schuell, Dassel, Germany). Dimethyl sulfoxide (DMSO) was also dispensed onto the membrane as a blank control. After undergoing rapid drying and crosslinking procedures, the preparation of the gene chip was complete. The gene chip was analyzed by the GenCling Enzymatic Gene Chip Detection Kit (MedicoGene Biotechnology Corp.) in accordance with the manufacturer's instructions. Total RNA was extracted from the peripheral blood of CRC patients. After performing complementary DNA (cDNA) synthesis and biotin labeling, the biotinlabeled probes hybridized with the well-established oligonucleotide chip. The chip then underwent a washing and blocking procedure, and subsequently reacted with streptavidin-alkyl phosphatase. The chip was incubated in chromogen solution containing nitroblue-tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP) while color developed. The hybridized arrays were then scanned with the Epson Perfection 1670 flat bed scanner (Seiko Epson Corp., Nagano, Japan). Sub sequent quantification analysis of each spot's intensity was per formed by using AlphaEase FC software (Alpha Innotech Corp., San Leandro, CA, USA). Spots consistently varying by a factor of two or more were considered as a differential expression.
Real-time quantitative PCR (RT-QPCR)
Real-time quantitative PCR was performed in a Rotor-Gene 2070 thermocycler (Corbett Research, Inc., Sydney, Australia). The reaction mixture contained 2 mL of 20 mM deoxyribonucleotide triphosphate (dNTP); 2 mL of 30 mM magnesium chloride; 2 mL of 20X SYBR green (Promega Corp, Madison, WI, USA); 2 mL of 1 mM forward primer; 2 mL of 1 mM reverse primer; 4 mL of nuclease free water; 2 mL of 80e100 ng/mL cDNA; and 2 mL of 1 U/mL polymerase. The PCR conditions were as follows: 35 cycles of denaturation at 95 C for 20 seconds, annealing at 60 C for 20 seconds, and extension at 74 C for 40 seconds. The PCR products [i.e., synthesized double-stranded DNA (dsDNA)] were quantified by measuring the fluorescent intensity at the end of each amplification cycle. To ensure the reproducibility of results of each sample, RT-QPCR analysis was repeated in three independent experiments.
Statistical analysis
All data were analyzed by using SPSS version 11.0 (SPSS, Inc., Chicago, IL, USA). The c
2 test was used to analyze the detection of disseminated tumor cells in peripheral blood by detection kit and the clinicopathological features. The difference between data obtained by the detection kit and by RT-QPCR was calculated by using linear regression and by Pearson's correlation. A p < 0.05 was considered statistically significant.
Results
Characteristics of patients
Thirty whole blood specimens were collected from CRC patients. Sixteen men (55.3%) and 14 women (46.7%) were recorded. The average age was 60.6 years (the age range was 30e77 years). Table 1 shows the clinicopathological characteristics of these 30 patients, who met the International Union Against Cancer (UICC) stage IeIII CRC criteria.
Differential expression profile of 31 CRC-related gene in colorectal cancers
The gene expression of 30 CRC patients was analyzed by the WEnCA platform with the GeneCling Enzymatic Gene Chip Detection Kit (Fig. 1) . Of the 31 CRC-related genes, nine genesdDVL1, ELAVL4, CHRNB1, UBE2C, PSAT1, CEA, MUC1  ENO2  MET  MYC  PTTG1  OLFM4  MMP13  CAP2  BMI1  CEA  CHRNB1  PSAT1   MUC1  ENO2  MET  MYC  PTTG1  OLFM4  MMP13  CAP2  BMI1  CEA  CHRNB1  PSAT1   PDE6D  FOXM1  UBE2C  TK1  CA9  CTHRC1  PDX1  ELAVL4  DVL1  CD55  TMPO  PSG2   PDE6D  FOXM1  UBE2C  TK1  CA9  CTHRC1  PDX1  ELAVL4  DVL1  CD55  TMPO  PSG2 Positive control Negative control PTTG1, KRT19, and hTERTdwere overexpressed in more than 90% of the CRC patients. Four genes were overexpressed in 70e90% of the patients, 12 genes were overexpressed in 50e70% of patients, and six genes were overexpressed in <50% of patients (Table 2 ). These overexpression rates are concordant with the data that were analyzed by using the original WEnCA operating procedure. However, the correlation between the 31 genes and the clinicopathological features of CRC patients showed no significant difference (data not shown).
Correlation between the GeneCling Enzymatic Gene Chip Detection Kit and RT-QPCR
To understand the correlation between the GeneCling Enzymatic Gene Chip Detection Kit and RT-QPCR, we analyzed gene expression by RT-QPCR. Using linear regression analysis, the gene expression ratio of the detection kit was highly consistent with RT-QPCR (r Z 0.901, p < 0.0001; Fig. 2) .
Discussion
In the present study, we demonstrated the overexpression pattern of 31 genes in CRC patients. Of the 31 genes, nine genesdDVL1, ELAVL4, CHRNB1, UBE2C, PSAT1, CEA, PTTG1, KRT19, and hTERTdhad an overexpression rate >90%. Three genes (DVL1, ELAVL4, and CHRNB1) of the nine genes had overexpression rates as high as 100%. The human homolog of the Drosophila disheveled (DVL1) gene, which is involved in Wnt pathway, is overexpressed in many cancers.
13e15 Embryonic lethal, abnormal vision, Drosophila-like 4 (ELAVL4), an RNA binding protein, is associated with neuronal cell maturation, malignant neuroblastoma, and Parkinson's disease. 16, 17 The cholinergic receptor, nicotinic, beta 1 (CHRNB1) gene encodes the beta subunit of the acetylcholine receptor that changes conformation on acetylcholine binding, leading to the opening of ion-conducting channel through the plasma membrane. The correlation between CHRNB1 and cancer is still unclear. However, because of the small sample size analyzed in this study, there was no significant correlation between the expression of the nine genes and the clinicopathological features of the CRC patients. Therefore, more samples are needed for further investigation to verify a clinical value.
Primary tumors can be detected the CTCs in the peripheral blood during the early stage of cancer. 18 Therefore, detecting CTCs in the peripheral blood could be a noninvasive method for diagnosing CRC. Based on our previous studies, WEnCA analysis for detecting molecular markers of CTCs has a very high sensitivity and specificity. The detection limitation of WEnCA assay is 12 cancer cells in 5 mL of blood. 11 The WEnCA platform is a good method for detecting CTCs in the peripheral blood of CRC patients.
In this study, the expression of 31 CRC-related genes was analyzed by the GeneCling Enzymatic Gene Chip Detection Kit, which was specifically developed for the WEnCA platform. A high consistency existed between the detection kit and RT-QPCR by comparing the gene expression ratio of these two methods in 30 CRC patients. The GeneCling Enzymatic Gene Chip Detection Kit comprises different procedures such as RNA extraction, cDNA synthesis, hybridization, washing and blocking, and color development that involve various reagents. These tests are simple to use, convenient, and fast, compared to previous methods that use kits of different brands for each step and that require individual adjustments to obtain optimal reaction conditions. With standard procedures and conditions for reactions, operating the WEnCA platform could become even more stable. The overall use of the GeneCling Enzymatic Gene Chip Detection Kit for WEnCA platform analysis is easy, convenient, and fairly stable. The pattern of gene expression can be understood by current analysis. Analysis of more samples is needed to explore the correlation between genetic differences and patients' clinicopathological features.
